Key statistics
On Friday, Context Therapeutics Inc (6K9:STU) closed at 1.82, -24.17% below its 52-week high of 2.40, set on Aug 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.90 |
---|---|
High | 1.90 |
Low | 1.82 |
Bid | 1.78 |
Offer | 1.87 |
Previous close | 1.90 |
Average volume | 0.00 |
---|---|
Shares outstanding | 75.00m |
Free float | 72.91m |
P/E (TTM) | -- |
Market cap | 146.25m USD |
EPS (TTM) | -1.06 USD |
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
Announcements
- Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results
- Context Therapeutics to Participate in Upcoming Investor Conferences in November
- Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
- BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
- Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors
- Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results
- Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations
- Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
- Context Therapeutics Reports First Quarter 2024 Operating and Financial Results
- Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76
More ▼